f you ask biotech investors today what they know about Arena Pharmaceuticals, nearly all will mention the weight-loss drug Belviq. Approved five years ago, it was touted as a potential blockbuster ― and ended up being a commercial flop.

Arena gave up on Belviq last January when it sold the rights to its Japanese partner, Eisai. Now, the company is developing three new drugs ― none of which has anything to do with obesity. The first in the pipeline, targeting a rare and debilitating lung disease, will read out study results later this month. With these new data, investors will get their first opportunity to assess Arena’s comeback strategy.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.